Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They do technically have more than enough to complete the trial, but with management like this you never know...
Nevermind, I did some math and updated the ibox with what should be the correct numbers as of March 20.
It's in their filings. Just search for "April 29".
For some reason they didn't include the remaining amount of each warrant series in the 10K this time.
Makes it a bit hard to update the numbers in the ibox.
Probably paid some company $1 million to help them with recruitment and retention of patients. For example by paying for transportation to/from the clinic and offering certain benefits for not dropping out early.
Just a guess though.
Didn't they measure synaptic growth in human brains quite a while ago? Sliced some human brains taken from dead patients and put them under a microscope.
Problem is how to measure it in people that are alive. Best they could do is measure PKCe levels in blood and see how it affects scores. Maybe this new imaging technique can solve that problem.
NBI (biotech index) has been declining for 6 months straight and central banks are about to hike rates, so it might take a while before you get your turnaround. Hopefully before the next fundraiser though so they don't have to dilute at bargain prices.
"Our work published today suggests we may be able to broaden the possible applicability of Bryostatin to more complicated dementias with more than one pathology beyond AD, such as Parkinson's, multi-infarct dementia, and Multiple Sclerosis."
https://www.prnewswire.com/news-releases/synaptogenix-to-present-research-highlighting-potential-broad-applicability-for-lead-compound-bryostatin-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-adpd-2022-301502928.html
It could even be delayed by 3-4 months. Some of the clinical sites are still accepting new patients at this moment.
Let's see what the 10K says about their financials. I have a feeling there's another dilution on the horizon before results.
Deadline for 10-K this year is March 31st, so they might not release it for another week or two.
Authors are usually ordered by how much they contribute to the paper, so the last place is usually reserved for the supervisor that is responsible for the research.
https://blog.wordvice.com/journal-article-author-order
Nah, Nasdaq Biotech Index is green today (for now at least).
Links for the emails can usually be found here:
https://www.prnewswire.com/news/synaptogenix%2C-inc./
I doubt it will reach $20 before results. Hell, it could even go under $5 if the trial takes too long and they need to raise more.
I agree. People shouldn't go to the casino with money they can't afford to lose.
Any ideas on what's taking them so long to finish recruiting for the current trial?
We're definitely not getting any results until 2023 now.
I think it's mostly index-related. SNPX has a beta of 1.3.
Worth mentioning is that these filings are dated December 31st 2021.
Couldn't help but pick up a few more at $7.15. Nasdaq is dropping today so of course this stock gets dragged down with the rest.
They had $31 million then but they burn through about $3 million each quarter, so I'm guessing they'll have about $16 million left by 2023.
That's certainly enough to complete the trial and get results out but like I said, you never know.
Nobody would've invested at that price. The shares being offered usually have their price set according to the average price for a set time period so investors don't get conned into buying the peak.
Plenty of April warrants could expire worthless but if they raise more cash before results that will significantly increase the share count again.
I'm currently using 20 million fully diluted shares for my future projections, but I have a feeling I might have to adjust it higher in the future.
Management has a history of questionable timing with their fundraisers so I wouldn't be surprised if they do another one in Q4. Hopefully they don't, but you never know with these people.
Eh, 30% is impressive but it did only reach $10 before going back down again.
We're still far away from all time highs. I'm even starting to worry about another dilution if this trial keeps dragging on into 2023.
Nah, the pooled results have been public since last year. No reason why this stock would blow up now on no results. When the stock market goes bad, this one will be dragged down along with the rest.
Great opportunity to get cheap shares before results though.
I do hold a base amount of shares no matter what for exactly the same reason you specified, but I also do some short term trading on top of that.
Not a strategy I would recommend for everyone, but it works for me.
Another opportunity to get in cheap and hop off once it goes up again lol
Buy below 100MA, sell above 100MA.
This stock isn't going anywhere until those results are out and my bet is it will keep swinging around the 100MA until results.
Completely random uneducated guess of course, but it does seem to get more true for each day that passes.
Their scientific results are still one of a kind imo. Who knows if that will translate to financial profits down the road, but I'm nevertheless excited to follow their progress.
That's how it goes with smaller biotechs. You either win big or lose big.
Good opportunity to accumulate more
Could get even tougher if rate hikes by the fed sink the whole stock market and drag this company down with the rest.
My guess is you will be able to pick some up below $8 not too long from now.
I don't mind the wait. Means there's more time for acquiring shares before results.
Lots of warrants that need to be exercised soon too which should keep the price under control.
These publishers don't deserve a nickel imo. Better to use someone else's institutional access or ask the author.
If the paper isn't too recent you can also use Sci-Hub.
Looks like supplemental data from their presentation last summer rather than an article. Either way, you don't need to pay for these papers since the corresponding author can legally send them to you for free. All you have to do is ask.
https://www.quora.com/What-is-the-protocol-for-contacting-an-author-of-a-scientific-paper-to-inquire-about-their-results
Probably because there's nothing noteworthy to announce. This is a very small company with very few employees.
Enrollment will probably continue for a few more weeks and new trials will probably take longer than that to get going.
Probably not getting enrollment finished this year if the trial takes 10 months and doesn't finish until early November.
Maybe in a month? That would mean new results could come out as late as early 2023.
Why not? This stock has traded below cash value before, and while I don't think it will happen again, I do think we'll get another opportunity to pick up shares below $7.
Lots of hype on this board about the article, PR and new trials, and while it will be exciting news for us that follow this company, I also think markets won't really care.
A lot of the recent patent applications/grants seem to be continuations of older patents.
Here's what Wikipedia says about those:
"For patents filed on or after June 8, 1995, under the TRIPS agreement, continuation patents expire 20 years from the date of filing of the parent patent application, regardless of when the patent is granted."
In this case, the original patent application was filed in 2015 which means the patent will expire in 2035.
It will be worth whatever investors are willing to pay for it, not what some random writer on SA thinks it will be worth.
Worth remembering is that this is a P2 trial and some investors may not take it seriously until they have a successful P3 trial.
Stock is swinging up and down in a predictable manner so it makes sense that shorts get in at these levels if they expect it to go back down to single digits.